Furthermore, in the APHINITY trial, 4805 HER2-positive breast cancer patients were randomly assigned to either pertuzumab or placebo with adjuvant chemotherapy plus trastuzumab [35] (Table 1). This evidence concerns the gene ERBB2 and breast carcinoma.